Journey Colab Looks to Mescaline for Treating Alcohol Use Disorder

An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.

Numinus’s Acquisition of Novamind May Signal More Consolidation to Come

Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”

A New Database Seeks to Prevent “Bad” Psychedelic Patents

Porta Sophia is building an online database of prior art pertaining to psychedelics with the goal of improving the flawed psychedelic patent process.

Funders at Johns Hopkins Shape The Future of Psychedelic Research

Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.

These Natural Psilocybin Droplets Come in Exact Dosages and Don’t Upset Your Stomach

Mimosa Therapeutics has created a cultured psilocybin mycelium product called Pearls that can be precisely dosed like synthetic psilocybin, but contains all the mushroom’s compounds.

Companies Eye Oregon’s Growing Psilocybin Business Boom

Retreats, converted ketamine clinics, patient management software, professional associations and other service providers ramp up for Oregon’s psilocybin gold rush.

Gabon Takes First Step Toward Legal Export of Sustainable Iboga

The NGO Blessings of the Forest is spearheading the new arrangement under the Nagoya Protocol, applying an international treaty to a psychedelic substance for the first time.

More Companies Embrace 5-MeO-DMT to Create Therapies

The psychedelic compound in toad venom is being used to develop therapies for everything from cluster headaches to chronic depression.

Scientists Create Cell-Based Psychedelic Toad Venom, a Potential 5-MeO-DMT “Bio-Factory”

The innovation may be the ethical alternative to the controversial practice of collecting Bufo toad venom.

Rick Doblin Explains MAPS’ New $70 Million Investment Fund With Vine Ventures

In an exclusive interview, Doblin discusses MAPS’s goal to raise $150 over the next three years, and their $70 million investment fund with Vine Ventures to help meet that funding goal.